Independent report
Medicines adaptive pathways for patients
Looks at issues relating to the ethics of medicines adaptive pathways for patients (MAPPs) including the use of real world data.
Documents
Details
Medicines adaptive pathways for patients (MAPPs) is an innovative, more adaptive approach to medicines development being discussed and piloted by the European Medicines Agency.
This report, which explores the views of patients and professionals, focusses on the MAPPs process but its findings could be applicable to similar early access schemes. It has therefore formed part of the evidence to inform the Accelerated Access Review.
The report, by the Centre for the Advancement of Sustainable Medical Innovation, was commissioned by the Department of Health and Office for Life Sciences.
Updates to this page
Published 22 March 2016